



July 2025





# Ophtalmics available

INN	STRENGTH	SHELF LIFE	PRESERVA TIVE FREE	PRESENTATIO N	THERAPY DAYS	STABILITY ZONE II	STABILITY ZONE IV	PRODU CT ML	STORAGE CONDITIONS	BATCH SIZE
Anti-allergy (	Anti-allergy (Eye drops solution)									
Olopatadine	1mg/ml	36 mont hs	Yes	Nemera Novelia ®	30 90	Yes Yes	No TBD	5.0 3 x 5.0	Store below 30oC. After first opening use in 90 days.	43 860
Anti- infectives Eye (Eye drops solution)										
Moxifloxacin	5mg/ml	24 mont hs	No	Regular bottle	30	Yes	No	5	Once opened - store for 28 days at a temperature below 30oC	40 000
Glaucoma (Eye drops solution)										
Bimatoprost	0.3mg /ml	24 mont hs	Yes	Nemera Novelia ®	30	Yes	No	3	Once opened, do not store above 25oC	70 423 25 510
Bimatoprost/ Timolol	(0.3mg / 5mg) /ml	24 mont hs	Yes	Nemera Novelia ®	30 90	Yes	No	3	Once opened, do not store above 25oC	70 423 25 510
Brimonidine	2mg /ml	24 mont hs	Yes	Nemera Novelia ®	30 90	Yes Yes	No No	5.0 3 x 5.0	Store below 30oC. After first opening use in 90 days.	43 103 43 103

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).

<sup>\*</sup>Polpharma Group API CA:

Dorzolamide	20mg/ml	24 mont hs	Yes	Nemera Novelia ®	30 60	Yes Yes	No No	5.0 10.0	Once opened, do not store above 25oC	45 455 22 727
Dorzolamide/Ti molol	(20mg/5m g) /ml	24 mont hs	Yes	Nemera Novelia ®	30 60	Yes Yes	No No	5.0 10.0	Once opened, do not store above 25oC	45 455 22 727
Latanoprost	0,05mg /ml	24 mont hs	Yes	Aeropump 3K	30 90	Yes Yes	In progress In progress	2.5 7.5	Do not freeze. Do not store above 25oC Zone IV- 90 days in use study in progress.	54 000 18 000
Latanoprost/Ti molol	(0.05mg / 5mg) / ml	Yes	Aeropum p 3K ®	30 90	In progress In progress	2.5 7.5	54 000 18 000			
Travoprost	0.04mg / ml	24 mont hs	Yes	Aeropump 3K	30 90	Yes Yes	In progress In progress	2.5 7.5	Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light.	55 000 22 000
Travoprost/Ti molol	(0.04mg / 5mg) / ml	24 mont hs	Yes	Aeropump 3K	30 90	In progress In progress	In progress In progress	2.5 7.5	Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light.	55 000 22 000
Acetazolamide	250mg	60 mont hs	No	Tablets	30	No	No	-	300 000	
Tropicamide	5mg/ml 10mg / ml	36 mont hs	No No	Regular bottle Regular bottle	30 30	Yes Yes	No No	2 x 5 2 x 5	Store below 25oC. After first opening use in 4 weeks.	192 000 594 000
Tobramycin / Dexamethaso ne	(3mg +1mg) /ml	24 mont hs	No	Regular bottle	30	Yes	No	5	Store below 25oC. After first opening use in 4 weeks.	40 000

#### \*Polpharma Group API CA:

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).

# Ophtalmics under development

INN	INDICATION	DEVELOPMENT PHASE
OR11	Red eye	Lab development
OD41	Dry eye	Lab development
OD31	Dry eye	Lab development
OIII	Infection	Lab development
021	Glaucoma	Lab development

#### \*Polpharma Group API CA:

Dossier suitable for Canadian market Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the poduct in the import market(s).



### **FARMAPROJECTS SAU**

Carrer Provença 392, 6ª Planta 08025 Barcelona (Spain) Phone +34 93 508 05 00 email: sales@farmaprojects.com

www.farmaprojects.com



